Sanam Loghavi, MD, stops by The HemOnc Pulse and chats with host Chadi Nabhan, MD, MBA, FACP, about why 2022 was significant for myelodysplastic syndromes (MDS) in this episode of the podcast.
“I think 2022 was a major year for myelodysplastic syndromes,” Dr. Loghavi said.
With the unveiling of the two new MDS classification systems in the past year, she breaks down the classification models and what it means for the specialty.
For example, the IPSS-M, published in 2022, is a “tremendous step forward” for MDS “in terms of prognostication and risk stratification,” Dr. Loghavi said, noting that she believes it may help guide the design of future clinical trials and therapies.
She also highlighted a group of abstracts from the 2022 American Society of Hematology Annual Meeting that she found significant.
“2022 was a big year for MDS, and I think you’ll see that reflected in the abstracts, because there are a lot of abstracts that are focused on validating these new classifications, or the IPSS, with their own real-world patient data,” Dr. Loghavi said.